POM-VPS Prescription Required

Bovilis Rotavec Corona Emulsion for Injection for Cattle

Active ingredients: Bovine coronavirus, Bovine rotavirus, Escherichia coli

Form

Injection

Species

Cattle

Manufacturer

Intervet International B.V.

VMD MA No.

06376/3034

What it's used for

While calves are fed colostrum from vaccinated cows during the first two to four weeks of life, these antibodies have been demonstrated to: - reduce the se...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bovine coronavirus + Bovine...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bovilis Rotavec Corona Emulsion for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

While calves are fed colostrum from vaccinated cows during the first two to four
weeks of life, these antibodies have been demonstrated to:
- reduce the severity of diarrhoea caused by E. coli F5 (K99) and F41
- reduce the incidence of scours caused by rotavirus
- reduce the shedding of virus by calves infected with rotavirus or coronavirus.
Onset of Immunity: Passive protection against all active substances will commence
from the start of colostrum feeding.
Duration of Immunity: In calves artificially fed with pooled colostrum, protection will
continue until colostrum feeding ceases. In naturally suckled
calves, protection against rotavirus will persist for at least 7 days
and against coronavirus for at least 14 days.

Preferably administer the vaccine in the side of the neck.
Shake well before use. Syringes and needles should be sterilised before use and the
injection should be made through an area of clean, dry skin taking precautions
against contamination.
Strict precautions should be taken against contamination of the vaccine. The use of a
multi-dose syringe is recommended to avoid excessive broaching of the stopper.
Once a vial is broached for the first time it may be used once more during the next 28
days and then discarded immediately after that use.
Administration:
Administer a single dose of 2 ml per animal. The recommended site of injection is the
side of the neck.
A single injection should be given during each pregnancy between 12 and 3 weeks
before calving is expected.
Colostrum feeding:
Protection of calves depends on the physical presence of colostrum antibodies (from
vaccinated cows) within the gut for the duration of the first 2 - 3 weeks of life until
calves develop their own immunity. Thus, it is essential to ensure adequate
colostrum feeding for the whole of this period to maximise the efficacy of vaccination.
All calves must receive adequate colostrum from their dams within 6 hours of birth.
Suckled calves will continue to receive adequate colostrum naturally by feeding from
vaccinated cows.
In the dairy herd colostrum/milk from the first 6 - 8 milkings of vaccinated cows
should be pooled. The colostrum may be stored below 20 °C, but should be used as
soon as possible as immunoglobulin levels may fall by up to 50% after storage for 28
days. Where possible, storage at 4 °C is recommended.
The calves should be fed on this pool at the rate of 2½ to 3½ litres per day
(according to body size) for the first two weeks of life.
Optimal results will be obtained if a whole herd cow vaccination policy is adopted.
This will ensure that in calves the level of infection and consequent virus excretion is
kept to a minimum and consequently the overall level of disease challenge on the
farm is minimised.

None.

Cattle (pregnant cows and heifers):
Very common
(>1 animal / 10 animals
treated):
Injection site swelling
, injection site pain
, injection
site warmth
, injection site granuloma
Muscle inflammation
Injection site abscess
Common
1 to 10 animals / 100 animals
treated:
Elevated temperature
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reaction
1
Intramuscular administration: Soft swelling raised up to 1 cm and a diameter of on
average 6.5 cm (maximum of 25 cm). Swellings usually resorb within 14 to 21 days
but may persist for 125 days.
Subcutaneous administration in the neck: Swelling raised up to 1 cm and ranged
from 2x2 to 15x15 cm (LxW). Swellings usually resorb over time but may persist for
125 days.
Injection site pain and injection site warmth occur reportedly commonly, when
administered intramuscularly.
After subcutaneous administration in the ischiorectal fossa.
Subcutaneous administration in the ischiorectal fossa resulted in granulomatous
haemorrhagic inflammatory reaction in dermal and subdermal tissues with
inflammation extending into the underlying muscular tissue.
Less than 1 cm in diameter after subcutaneous administration in the ischiorectal
fossa.
Intramuscular administration: Average increase of 0.4 °C, with a maximum of more
than 2.0 °C, returning to normal the day after vaccination.
Subcutaneous administration in the ischiorectal fossa: Average increase of 0.4 °C,
with a maximum of more than 2.0 °C, returning to normal in one to two days after
vaccination.
In such cases, appropriate treatment such as adrenaline should be administered
without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-
medicine
e-mail: [email protected]

Vaccinate healthy animals only.

Special precautions for safe use in the target species:
Administration in the ischiorectal fossa resulted in local painful chronic
granulomatous reactions up to 12 cm in diameter and in abscess formation (up to 1
cm in diameter at post mortem 19 weeks after the first vaccination).
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
To the user:
This veterinary medicinal product contains mineral oil. Accidental injection/self-
injection may result in severe pain and swelling, particularly if injected into a joint or
finger, and in rare cases could result in the loss of the affected finger if prompt
medical attention is not given. If you are accidentally injected with this veterinary
medicinal product, seek prompt medical advice even if only a very small amount is
injected and take the package leaflet with you. If pain persists for more than 12 hours
after medical examination, seek medical advice again.
To the physician:
This veterinary medicinal product contains mineral oil. Even if small amounts have
been injected, accidental injection with this veterinary medicinal product can cause
intense swelling, which may, for example, result in ischaemic necrosis and even the
loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate
early incision and irrigation of the injected area, especially where there is involvement
of finger pulp or tendon.
Special precautions for the protection of the environment:
Not applicable.

Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day but not mixed with Bovilis Cryptium. The vaccines
should be given at different sites.
The product literature of Bovilis Cryptium should be consulted before administration.
After non-mixed associated use injection site swellings raised up to 1 cm and a
diameter of on average 7.6 cm (maximum of 30 cm) can be observed. Swellings
usually resorb within 14 to 21 days but may persist for 18 weeks.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the product mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.
Protect from light.
After broaching and first use, store upright and refrigerated (2 – 8 °C) until the next
vaccination event.

Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.